Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials.

[1]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[2]  G. Stone,et al.  Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. , 2016, Journal of the American College of Cardiology.

[3]  P. Jüni,et al.  Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[4]  Sunil V. Rao,et al.  Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial , 2015, The Lancet.

[5]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[6]  B. Gersh,et al.  Do current clinical trials meet society's needs?: a critical review of recent evidence. , 2014, Journal of the American College of Cardiology.

[7]  E. Omerovic,et al.  Outcomes 1 year after thrombus aspiration for myocardial infarction. , 2014, The New England journal of medicine.

[8]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[9]  S. Kaul.  Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.

[10]  P. Kolh,et al.  Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis , 2014, BMJ : British Medical Journal.

[11]  Maurice Buchbinder,et al.  Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.

[12]  Tim Friede,et al.  Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data , 2014, Pharmaceutical statistics.

[13]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[14]  N. Simon,et al.  Adaptive enrichment designs for clinical trials. , 2013, Biostatistics.

[15]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[16]  Akshay S. Desai,et al.  Treatment of anemia with darbepoetin alfa in systolic heart failure. , 2013, The New England journal of medicine.

[17]  G. Guyatt,et al.  How to use a noninferiority trial: users' guides to the medical literature. , 2012, JAMA.

[18]  J. McMurray,et al.  When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches , 2012, Circulation. Heart failure.

[19]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[20]  T. Huber,et al.  Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients , 2012 .

[21]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[22]  Cyrus R Mehta,et al.  Adaptive increase in sample size when interim results are promising: A practical guide with examples , 2011, Statistics in medicine.

[23]  F. Harrell,et al.  Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. , 2011, American heart journal.

[24]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[25]  Á. Chamorro,et al.  Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial , 2011, The Lancet.

[26]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[27]  Deepak L. Bhatt,et al.  APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* , 2011 .

[28]  S. Werns.  Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes , 2011 .

[29]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[30]  S. Yusuf,et al.  Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. , 2010, The New England journal of medicine.

[31]  Draft Guidance.  Guidance for Industry Non-Inferiority Clinical Trials , 2010 .

[32]  Draft Guidance.  Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .

[33]  Gregg W Stone,et al.  Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.

[34]  B. Gersh,et al.  Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. , 2009, The New England journal of medicine.

[35]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[36]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[37]  J. Lachin.  Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit , 2009, Clinical trials.

[38]  Cyrus Mehta,et al.  Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.

[39]  K. Bailey,et al.  From randomized trials to registry studies: translating data into clinical information , 2008, Nature Clinical Practice Cardiovascular Medicine.

[40]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[41]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[42]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[43]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[44]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[45]  Stuart J Pocock,et al.  Current controversies in data monitoring for clinical trials , 2006, Clinical trials.

[46]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[47]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[48]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[49]  Sydes,et al.  A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.

[50]  Alan A Montgomery,et al.  Design, analysis and presentation of factorial randomised controlled trials , 2003, BMC medical research methodology.

[51]  D. Stryer,et al.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.

[52]  G. Stone,et al.  Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.

[53]  Peter Sleight,et al.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.

[54]  David L. DeMets,et al.  Data Monitoring Committees in Clinical Trials: A Practical Perspective , 2002 .

[55]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[56]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[57]  S J Pocock,et al.  Randomized trials or observational tribulations? , 2000, The New England journal of medicine.

[58]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[59]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[60]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[61]  D. DeMets,et al.  The agonising negative trend in monitoring of clinical trials , 1999, The Lancet.

[62]  W F Rosenberger,et al.  Randomized play-the-winner clinical trials: review and recommendations. , 1999, Controlled clinical trials.

[63]  J. Ware,et al.  Equivalence trials. , 1997, The New England journal of medicine.

[64]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[65]  S. Pocock,et al.  Factorial trials in cardiology: pros and cons. , 1994, European heart journal.